• Contact
  • Location
  • Sitemap
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
    • Contacts
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press Releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
    • Contacts
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press Releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsCorporate GovernanceNomination Committee

Investors

  • Overview
  • Press releases
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads
  • Contacts

Nomination Committee

The members of the nomination committee shall, irrespective of how they are appointed, attend to the interests of all shareholders. The annual general meeting resolves how the nomination shall be appointed.

Nomination Committee of the Annual General Meeting 2019

In accordance with the principles of appointing the nomination committee, adopted by the annual general meeting of 25 April 2018, the chairman of the board of directors has contacted the major shareholders in order to appoint a nomination committee. The nomination committee of Immunicum consist of the four members appointed by the four largest shareholders that have accepted the invitation to participate in the nomination committee.

The nomination committee before the annual general meeting of 2019 is convened by the chairman of Immunicum’s board of directors Michael Oredsson and consists of  Martin Lindström (appointed by Loggen Invest AB), Jannis Kitsakis (appointed by AP4), Johan Sjöström (appointed by AP2) and Jamal El-Mosleh, (appointed by BISP Invest AB). The nomination committee’s assignment is to prepare the following proposals to the annual general meeting of 2019: (i) proposal of nomination of the chairman of the annual general meeting; (ii) proposal of nomination of board members; (iii) proposal of nomination of the chairman of the board of directors; (iv) proposal of the remuneration to the board of directors; (v) proposal of nomination of auditors (if instructed pursuant to Chapter 8 Section 49 b Paragraph 2 of the Companies Act); (vi) proposal of remuneration to the auditors; and (vii) proposal of principles of the nomination committee before the annual general meeting of 2020.

The annual general meeting in Immunicum will be held on 25 April 2019.

Shareholders who wish to leave proposal to the nomination committee can do so by email to martin@loggeninvest.se or by letter to Immunicum AB (publ), Att: Valberedningen, Östermalmstorg 5, 114 42 Stockholm

Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us
Stockholm

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 31 41 50 52

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2019 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve